Comments
Taro Pharmaceutical Industries Ltd, the US subsidiary of Sun Pharmaceuticals Industries Ltd , has received tentative approval from the US Food and Drug Administration for diclofenac sodium topical solution of 2 per cent strength. Diclofenac sodium is indicated for mild to moderate pain, or signs and symptoms of osteoarthritis or rheumatoid arthritis. Sun Pharma shares edged down 1 per cent at ₹662.3 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.